查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586048

癌症切片檢查市場：按產品類型、適應症分類 - 2025-2030 年全球預測

Cancer Biopsy Market by Product (Instruments, Kits & Consumables, Services), Type (Liquid Biopsies, Tissue Biopsies), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症切片檢查市場價值為298.4億美元，預計到2024年將達到334.8億美元，複合年成長率為12.28%，預計到2030年將達到671.4億美元。

癌症切片檢查市場包括一系列收集組織樣本以進行癌症診斷和監測的程序。切片檢查對於提供癌症的明確診斷並幫助醫生製定有效的治療策略至關重要。該市場包括針活體組織切片和切片檢查等傳統技術，以及分析體液中生物標記的液態切片等新技術。全球癌症發生率不斷上升以及對微創診斷工具的需求不斷成長，強調了對切片檢查的需求。切片檢查用於多個最終用途領域，包括醫院、診斷中心和研究機構。該市場的主要成長動力包括切片檢查技術的進步、個人化醫療的持續採用以及醫療保健支出的增加。人工智慧驅動的影像診斷和分析工具的開發為簡化診斷和提高準確性提供了重要機會。然而，市場面臨一些限制，例如先進切片檢查方法的相對成本、監管障礙以及患者不願接受侵入性手術。挑戰包括缺乏熟練的專業人員以及資源匱乏環境中的技術差距。對於公司而言，液態切片等非侵入性切片檢查技術的創新至關重要，因為它們具有早期檢測癌症的潛力。此外，投資自動切片檢查技術和即時資料分析系統可以增強您的市場地位並有助於制定個人化治療計劃。在技​​術快速發展的推動下，市場競爭激烈，因此企業需要透過持續的研發努力來保持領先地位。至關重要的是，公司應專注於與研究機構的合作，以促進創新並擴大應用可能性。總體而言，透過優先考慮可訪問性、成本效益和技術整合，公司可以有效地應對不斷變化的市場環境並抓住新機會。

主要市場統計
基準年[2023] 298.4億美元
預測年份 [2024] 334.8億美元
預測年份 [2030] 671.4億美元
複合年成長率（%） 12.28%

市場動態：揭示快速發展的癌症切片檢查市場的關鍵市場洞察

供需的動態交互作用正在改變癌症切片檢查市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 人們越來越偏好非侵入性手術
    • 癌症切片檢查和組織切片的重要性日益增加
    • 擴大液體癌症切片檢查的採用
  • 市場限制因素
    • 癌症切片檢查的敏感性和特異性低
  • 市場機會
    • 切片檢查設備的技術進步
    • 活性化新癌症治療方法的研發活動
  • 市場挑戰
    • 嚴格的監管要求和不確定的贖回場景

波特五力：駕馭癌症切片檢查市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解癌症切片檢查市場的外部影響

外部宏觀環境因素在塑造切片檢查市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解切片檢查市場的競爭格局

對癌症切片檢查市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣癌症切片檢查市場供應商的績效評估

FPNV 定位矩陣是評估切片檢查市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了切片檢查市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對癌症切片檢查市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對非侵入性手術的偏好日益增加
      • 癌症切片檢查和組織切片的新重要性
      • 更多地採用液體癌症切片檢查
    • 抑制因素
      • 癌症切片檢查的敏感性和特異性較低
    • 機會
      • 切片檢查設備的技術進步
      • 加強新癌症治療方法的研發活動
    • 任務
      • 監管要求嚴格，贖回場景不明確
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癌症切片檢查市場：依產品

  • 裝置
  • 套件和用品
  • 服務

第7章癌症切片檢查市場：按類型

  • 液態生物檢體
  • 組織切片檢查
    • 針吸切片
      • 空心針活體組織切片
      • 細針穿刺法
    • 切片檢查

第8章癌症切片檢查市場（按適應症）

  • 血癌
  • 乳癌
  • 子宮頸癌
  • 大腸直腸癌
  • 腎癌
  • 肝癌
  • 肺癌
  • 卵巢癌
  • 胰臟癌
  • 攝護腺癌
  • 皮膚癌

第9章美洲癌症切片檢查市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太癌症切片檢查市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的癌症切片檢查市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Agena Bioscience, Inc.
  • Agilent Technologies Inc.
  • ANGLE PLC
  • Becton, Dickinson and Company
  • BIOCEPT, Inc.
  • Danaher Corporation
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Freenome Holdings, Inc.
  • GRAIL, Inc.
  • Guardant Health
  • HelioHealth
  • Hologic, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • MDx Health
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • OncoCyte Corp
  • Personalis Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific, Inc.
  • Trovagene, Inc
Product Code: MRR-C27187914300

The Cancer Biopsy Market was valued at USD 29.84 billion in 2023, expected to reach USD 33.48 billion in 2024, and is projected to grow at a CAGR of 12.28%, to USD 67.14 billion by 2030.

The cancer biopsy market encompasses the array of procedures used to extract tissue samples for the diagnosis and monitoring of cancerous growths. Biopsies are crucial as they provide definitive cancer diagnoses, enabling physicians to devise effective treatment strategies. This market includes traditional techniques like needle and surgical biopsies, as well as emerging methods such as liquid biopsies, which analyze biomarkers in bodily fluids. The necessity of biopsies is underscored by the increasing global incidence of cancer and the growing demand for less invasive diagnostic tools. Biopsies find application across multiple end-use segments, including hospitals, diagnostic centers, and research institutes. Key growth drivers for this market include advancements in biopsy technologies, the rising adoption of personalized medicine, and increased healthcare spending. The development of AI-driven imaging and analysis tools presents significant opportunities, streamlining diagnosis and improving accuracy. However, the market faces limitations such as the relatively high cost of advanced biopsy methods, regulatory hurdles, and patient reluctance towards invasive procedures. Challenges also include the scarcity of skilled professionals and technological gaps in low-resource settings. For businesses, innovation in non-invasive biopsy techniques like liquid biopsy can be pivotal, given its potential to detect cancers at an earlier stage. Furthermore, investing in automated biopsy technologies and real-time data analysis systems can enhance market position and contribute to personalized treatment plans. The market is competitive, driven by rapid technological evolution, thus requiring companies to stay ahead with ongoing R&D efforts. It's crucial for businesses to focus on collaborations with research institutes to foster innovation and expand applicability. Overall, by prioritizing accessibility, cost-effectiveness, and technological integration, companies can effectively navigate this evolving market landscape and capitalize on emerging opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 29.84 billion
Estimated Year [2024] USD 33.48 billion
Forecast Year [2030] USD 67.14 billion
CAGR (%) 12.28%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biopsy Market

The Cancer Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing preference for non-invasive procedures
    • Emerging significance of cancer biopsies and tissue sectioning
    • Growing adoption of liquid cancer biopsies
  • Market Restraints
    • Low sensitivity and specificity of cancer biopsies
  • Market Opportunities
    • Technological advancements in cancer biopsy devices
    • Increasing R&D activities for novel cancer treatments
  • Market Challenges
    • Stringent regulatory requirements and unclear reimbursement scenarios

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biopsy Market

A detailed market share analysis in the Cancer Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biopsy Market

A strategic analysis of the Cancer Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biopsy Market, highlighting leading vendors and their innovative profiles. These include Agena Bioscience, Inc., Agilent Technologies Inc., ANGLE PLC, Becton, Dickinson and Company, BIOCEPT, Inc., Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Freenome Holdings, Inc., GRAIL, Inc., Guardant Health, HelioHealth, Hologic, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., MDx Health, Myriad Genetics, Inc., Natera, Inc., OncoCyte Corp, Personalis Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., and Trovagene, Inc.

Market Segmentation & Coverage

This research report categorizes the Cancer Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Instruments, Kits & Consumables, and Services.
  • Based on Type, market is studied across Liquid Biopsies and Tissue Biopsies. The Tissue Biopsies is further studied across Needle Biopsies and Surgical Biopsies. The Needle Biopsies is further studied across Core Needle Biopsy and Fine Needle Aspiration.
  • Based on Indication, market is studied across Blood Cancers, Breast Cancer, Cervical Cancers, Colorectal Cancer, Kidney Cancers, Liver Cancers, Lung Cancers, Ovarian Cancers, Pancreatic Cancers, Prostate Cancers, and Skin Cancers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing preference for non-invasive procedures
      • 5.1.1.2. Emerging significance of cancer biopsies and tissue sectioning
      • 5.1.1.3. Growing adoption of liquid cancer biopsies
    • 5.1.2. Restraints
      • 5.1.2.1. Low sensitivity and specificity of cancer biopsies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in cancer biopsy devices
      • 5.1.3.2. Increasing R&D activities for novel cancer treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements and unclear reimbursement scenarios
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Biopsy Market, by Product

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Kits & Consumables
  • 6.4. Services

7. Cancer Biopsy Market, by Type

  • 7.1. Introduction
  • 7.2. Liquid Biopsies
  • 7.3. Tissue Biopsies
    • 7.3.1. Needle Biopsies
      • 7.3.1.1. Core Needle Biopsy
      • 7.3.1.2. Fine Needle Aspiration
    • 7.3.2. Surgical Biopsies

8. Cancer Biopsy Market, by Indication

  • 8.1. Introduction
  • 8.2. Blood Cancers
  • 8.3. Breast Cancer
  • 8.4. Cervical Cancers
  • 8.5. Colorectal Cancer
  • 8.6. Kidney Cancers
  • 8.7. Liver Cancers
  • 8.8. Lung Cancers
  • 8.9. Ovarian Cancers
  • 8.10. Pancreatic Cancers
  • 8.11. Prostate Cancers
  • 8.12. Skin Cancers

9. Americas Cancer Biopsy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Biopsy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Biopsy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agena Bioscience, Inc.
  • 2. Agilent Technologies Inc.
  • 3. ANGLE PLC
  • 4. Becton, Dickinson and Company
  • 5. BIOCEPT, Inc.
  • 6. Danaher Corporation
  • 7. Epigenomics AG
  • 8. Exact Sciences Corporation
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. Freenome Holdings, Inc.
  • 11. GRAIL, Inc.
  • 12. Guardant Health
  • 13. HelioHealth
  • 14. Hologic, Inc.
  • 15. Illumina, Inc.
  • 16. Laboratory Corporation of America Holdings
  • 17. Lucence Health Inc.
  • 18. MDx Health
  • 19. Myriad Genetics, Inc.
  • 20. Natera, Inc.
  • 21. OncoCyte Corp
  • 22. Personalis Inc.
  • 23. QIAGEN N.V.
  • 24. Thermo Fisher Scientific, Inc.
  • 25. Trovagene, Inc

LIST OF FIGURES

  • FIGURE 1. CANCER BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER BIOPSY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER BIOPSY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER BIOPSY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER BIOPSY MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY KITS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIQUID BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOPSY MARKET SIZE, BY BLOOD CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOPSY MARKET SIZE, BY CERVICAL CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOPSY MARKET SIZE, BY KIDNEY CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOPSY MARKET SIZE, BY OVARIAN CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOPSY MARKET SIZE, BY PANCREATIC CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOPSY MARKET SIZE, BY SKIN CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CANCER BIOPSY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY TISSUE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY NEEDLE BIOPSIES, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 241. CANCER BIOPSY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. CANCER BIOPSY MARKET, FPNV POSITIONING MATRIX, 2023